Peptinov’s drug design products (small molecule inhibitors)

Anti-TNF small molecule inhibitor

Peptinov has developed a small molecule TNF inhibitor through its drug design platform.

This anti-TNF inhibitor showed the following results:
– In vitro inhibition of TNF activity in cellular assays,
– Demonstration of in vitro inhibition of TNF/TNF-R interaction,
– Effective binding to TNF,
– Per os and i.p. protective effect in the LPS/D-Gal septic shock mouse model (which is TNF-dependent).

This anti-TNF product is to the extent of our knowledge the only direct TNF small molecule inhibitor currently in development. An optimization phase is underway in order to start the pre-clinical and clinical development in 2015.


Other anti-cytokine products in development

Peptinov is currently developing products against different cytokines with its drug design platform: IL6, IL23p19, IL1b, IL4, IL13 and IL33. Hit compounds have already been identified and the screening is underway.

Several cytokines are also being investigated with the active immunization platform.